Fresenius USA Net Profits Leap 176%
Fresenius USA Inc, the subsidiary of the German medical equipment, dialysis and pharmaceuticals group Fresenius AG, has reported a 19% rise in fourth-quarter 1995 net sales to $81.1 million and a 19.9% increase from 1995 as a whole to $305 million.
Net profit in the final quarter of 1995 went up from $2.1 million to $5.8 million, a rise of some 176%. Higher volume sales of hemodialysis and peritoneal dialysis products boosted fourth-quarter sales and earnings. Earnings per share in the quarter were 21 cents compared with 9 cents in the like, 1994 quarter. EPS for the year was 59 cents, up from 31 cents. Fresenius is currently negotiating a merger with W R Grace's dialysis unit (see page 3).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze